A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Chugai Pharmaceutical

Status and phase: Completed; Phase 3

Conditions: Chemotherapy Induced Anemia

Treatments: Drug: recombinant human erythropoietin placebo; Drug: recombinant human erythropoietin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00144482

EPO307JP

Details and patient eligibility

About

To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy

Enrollment: 122 patients

Sex: All

Ages: 20 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cancer patients

Exclusion criteria

• a history of myocardial, cerebral or pulmonary infarction
• severe hypertension beyond control by drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

122 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: recombinant human erythropoietin

2

Placebo Comparator group

Treatment:

Drug: recombinant human erythropoietin placebo